CMP
NWBO

Coston McIsaac & Partners’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Coston McIsaac & Partners’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Hold
1,000
– – ﹤0.01% 950
2026
Q1 		$0 Hold
1,000
– – ﹤0.01% 936
2025
Q4 		$0 Hold
1,000
– – ﹤0.01% 934
2025
Q3 		$0 Hold
1,000
– – ﹤0.01% 877
2025
Q2 		$0 Buy
+1,000
New – ﹤0.01% 856
2025
Q1 		– Sell
-1,000
Closed – – 861
2024
Q4 		$0 Hold
1,000
– – ﹤0.01% 858
2024
Q3 		$0 Hold
1,000
– – ﹤0.01% 839
2024
Q2 		$0 Hold
1,000
– – ﹤0.01% 823
2024
Q1 		$0 Hold
1,000
– – ﹤0.01% 804
2023
Q4 		$0 Hold
1,000
– – ﹤0.01% 800
2023
Q3 		$0 Buy
+1,000
New – ﹤0.01% 821

Other funds holding NWBO

CFM
Compass Financial Management Tampa, Florida $829M AUM
KFA
Kelleher Financial Advisors New York $705M AUM 16.14% 1-Year Est. Return
VWA
VSM Wealth Advisory Hunt Valley, Maryland $376M AUM 21.56% 1-Year Est. Return
OCG
Opus Capital Group Cincinnati, Ohio $1.03B AUM 20.67% 1-Year Est. Return
EFG
Ethos Financial Group King Of Prussia, Pennsylvania $1.5B AUM 22.75% 1-Year Est. Return
WJWM
Williams Jones Wealth Management New York $8.86B AUM 22.16% 1-Year Est. Return

Coston McIsaac & Partners's NWBO Position: Q2 2026 in Review

Coston McIsaac & Partners held its Northwest Biotherapeutics, Inc. Common stock (NWBO) position steady in Q2 2026 at 1,000 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #950.

Coston McIsaac & Partners first reported a position in NWBO in Q3 2023 and has held it in 11 quarters since. 8 funds tracked by Wall St. Rank hold NWBO as of Q2 2026.

  • Coston McIsaac & Partners held 1,000 shares of Northwest Biotherapeutics, Inc. Common stock worth $0 as of Q2 2026.
  • Coston McIsaac & Partners left its Northwest Biotherapeutics, Inc. Common stock share count unchanged in Q2 2026.
  • Northwest Biotherapeutics, Inc. Common stock made up ﹤0.01% of Coston McIsaac & Partners's portfolio in Q2 2026, its #950 holding.
  • Coston McIsaac & Partners first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q3 2023 and has held it in 11 quarters since.
  • 8 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q2 2026.

Based on Coston McIsaac & Partners's 13F filing for Q2 2026, filed 12 Aug 2026.